ValuEngine upgraded shares of Check-Cap Ltd. (NASDAQ:CHEK) from a strong sell rating to a sell rating in a report released on Thursday morning.

CHEK has been the topic of a number of other research reports. Zacks Investment Research downgraded Check-Cap from a buy rating to a hold rating in a report on Tuesday, May 23rd. Maxim Group reiterated a buy rating on shares of Check-Cap in a report on Tuesday, May 30th. Finally, HC Wainwright set a $6.00 target price on Check-Cap and gave the stock a buy rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $5.00.

Shares of Check-Cap (NASDAQ CHEK) opened at 1.7193 on Thursday. The firm’s market cap is $29.19 million. The firm has a 50-day moving average price of $1.83 and a 200-day moving average price of $2.03. Check-Cap has a 52 week low of $1.65 and a 52 week high of $2.95.

Check-Cap (NASDAQ:CHEK) last posted its earnings results on Thursday, August 10th. The medical research company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.01. On average, equities research analysts predict that Check-Cap will post ($0.63) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/21/check-cap-ltd-chek-stock-rating-upgraded-by-valuengine.html.

An institutional investor recently raised its position in Check-Cap stock. Knott David M boosted its position in Check-Cap Ltd. (NASDAQ:CHEK) by 1.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 162,871 shares of the medical research company’s stock after buying an additional 3,000 shares during the period. Knott David M owned approximately 1.05% of Check-Cap worth $349,000 at the end of the most recent quarter. Institutional investors own 13.35% of the company’s stock.

Check-Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related stocks with our FREE daily email newsletter.